Drug resistance mutations in patients infected with HIV-2 living in Spain

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 7, 2011, Pages 1484-1488

  Trevinõ, Ana ^a   de Mendoza, Carmen ^a   Caballero, Estrella ^b   Rodríguez, Carmen ^c   Parra, Patricia ^a   Benito, Rafael ^d   Cabezas, Teresa ^e   Roc, Lourdes ^f   Aguilera, Antonio ^g   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c CENTRO SANITARIO SANDOVAL   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e HOSPITAL DE PONIENTE   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g HOSPITAL DE CONXO   (Spain)

Author keywords

Integrase; Protease; Reverse transcriptase

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INDINAVIR PLUS RITONAVIR; INTEGRASE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; THYMIDINE DERIVATIVE; TIPRANAVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; SEQUENCE ANALYSIS; SPAIN; VIREMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-2; HUMANS; INTEGRASES; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; SPAIN; VIRAL PROTEINS; YOUNG ADULT;

EID: 79958823885     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr164     Document Type: Article

References (32)

1. Poulsen A, Aaby P, Gottschau A et al. HIV-2 infection in Bissau, West Africa, 1987-1989: incidence, prevalence, and routes of transmission. J Acquir mmune Defic Syndr 1993; 6: 941-8.
2. Reeves J, Doms R. Human immunodeficiency virus type 2. J Gen Virol 2002; 83: 1253-65.
3. Hizi A, Tal R, Hughes S. Mutational analysis of the DNA polymerase and ribonuclease H activities of HIV type 2 reverse transcriptase expressed in Escherichia coli. Virology 1991; 180: 339-46.
4. Ohtaka H, Freire E. Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol 2005; 88: 193-208.
5. Roquebert B, Damond F, Collin G et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62: 914-20.
6. Ntemgwa M, d'Aquin T, Brenner B et al. Antiretroviral drug resistance in HIV type 2. Antimicrob Agents Chemother 2009; 53: 3611-9.
7. Parkin N, Schapiro J. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004; 9: 3-12.
8. Witvrouw M, Pannecouque C, Switzer W et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and ost-exposure prophylaxis. Antivir Ther 2004; 9: 57-65.
9. Poveda E, Rodes B, Toro C et al. Are fusion inhibitors active against all HIV variants? AIDS Res Human Retroviruses 2004; 20: 347-8.
10. Colson P, Henry M, Tourres C et al. Polymorphism and drug-selected mutations in the protease gene of HIV type 2 from patients living in Southern France. J lin Microbiol 2004; 42: 570-7.
11. Rodés B, Sheldon J, Toro C et al. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob hemother 2006; 57: 709-13.
12. Brower E, Bacha U, Kawasaki Y et al. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008; 71: 298-305.
13. Desbois D, Roquebert B, Peytavin G et al. In vitro phenotypic susceptibility of HIV-2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 008; 52: 1545-8.
14. Damond F, Lariven S, Roquebert B et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected atients. AIDS 2008; 22: 665-6.
15. Little S, Holte S, Routy J et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
16. de Mendoza C, Rodriguez C, Colomina J et al. Resistance to non-nucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 2005; 41: 1350-4.
17. Jallow S, Vincent T, Leligdowicz A et al. Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio, uinea Bissau. Clin Infect Dis 2009; 48: 1790-3.
18. Silva JC, Gonçalves MF, van Laethem K et al. Transmission of drug resistance in HIV-2-infected patients. Antivir Ther 2010; 15 Suppl 2: 182.
19. Rodés B, Holguín A, Soriano V et al. Emergence of drug resistance mutations in HIV type 2-infected subjects undergoing antiretroviral therapy. J Clin icrobiol 2000; 38: 1370-4.
20. Johnson V, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17: 138-45.
21. Alcantara L, Cassol S, Libin P et al. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral equences. Nucleic Acids Res 2009; 37: W634-42.
22. De Mendoza C, Anta L, García F et al. HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. AIDS Rev 2009; 11: 39-51.
23. Damond F, Matheron S, Peytavin G et al. Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen. Antivir Ther 2004; 9: 635-6.
24. Descamps D, Damond F, Matheron S et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74: 197-201.
25. Gottlieb G, Badiane N, Hawes S et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis 2009; 48: 476-83.
26. Cavaco-Silva J, Miranda A, Cabanas J et al. Amino acid substitutions selected by therapy in HIV-2 protease and reverse transcriptase. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009. Abstract 663. Foundation for Retrovirology and Human Health, lexandria, VA, USA.
27. Ntemgwa M, Brenner B, Oliveira M et al. Natural polymorphisms in the HIV type 2 protease can accelerate time to development of resistance to protease nhibitors. Antimicrob Agents Chemother 2007; 51: 604-10.
28. Cavaco-Silva J, Thies K, Miranda A et al. Bayesian network analysis of resistance pathways in HIV-2 protease. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 560. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
29. Cavaco-Silva J, Thies K, Gonçalves MF et al. Bayesian network analysis of resistance pathways in HIV-2 reverse transcriptase. In: Abstracts of the Eighth European HIV Drug Resistance Workshop, Sorrento, Italy, 2010. Abstract 46. Rev Antivir Ther Infect Dis 2010; 1: 44-5.
30. Rodés B, Toro C, Sheldon J et al. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 2006; 20: 127-9.
31. Smith R, Ba S, Hawes S et al. Toward optimal ART for HIV-2 infection: can genotypic and phenotypic drug resistance testing Help Guide Therapy in HIV-2? In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 5790. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
32. Salgado M, Toro C, Simón A et al. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J lin Virol 2009; 46: 173-5.